A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

• Published in: Neurology Vol. 66; no. 6; p. 894
• Main Authors: O'Connor, P W, Li, D, Freedman, M S, Bar-Or, A, Rice, G P A, Confavreux, C, Paty, D W, Stewart, J A, Scheyer, R
• Format: Journal Article
• Language: English
• Published: United States 28.03.2006
• Subjects: Adult; Double-Blind Method; Female; Headache - chemically induced; Humans; Immunologic Factors - adverse effects; Immunologic Factors - metabolism; Immunologic Factors - therapeutic use; Isoxazoles - adverse effects; Isoxazoles - metabolism; Isoxazoles - therapeutic use; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting - drug therapy; Multiple Sclerosis, Relapsing-Remitting - physiopathology; Nausea - chemically induced
• ISSN: 1526-632X
• DOI: 10.1212/01.wnl.0000203121.04509.31

Teriflunomide, a dihydro-orotate dehydrogenase inhibitor, has immunomodulatory effects, including the ability to suppress experimental allergic encephalomyelitis. In this randomized, double-blind, placebo-controlled Phase II study, the authors examined the safety and efficacy of oral teriflunomide in multiple sclerosis (MS) with relapses. Patients (n = 179) with relapsing-remitting MS (n = 157) or secondary progressive MS with relapses (n = 22) were randomized to receive placebo, teriflunomide 7 mg/day, or teriflunomide 14 mg/day for 36 weeks. MRI brain scans were performed every 6 weeks. The primary endpoint was the number of combined unique active lesions per MRI scan. Secondary endpoints included MRI-defined disease burden, relapse frequency, and disability increase. The median number of combined unique active lesions per scan was 0.5, 0.2, and 0.3 in the placebo, teriflunomide 7 mg/day (p < 0.03 vs placebo), and teriflunomide 14 mg/day (p < 0.01 vs placebo) groups during the 36-week double-blind treatment phase. Teriflunomide-treated patients also had significantly fewer T1 enhancing lesions per scan, new or enlarging T2 lesions per scan, and new T2 lesions. Patients receiving teriflunomide 14 mg/day had significantly reduced T2 disease burden. Teriflunomide treatment resulted in trends toward a lower annualized relapse rate and fewer relapsing patients (14 mg/day only) vs placebo. Significantly fewer patients receiving teriflunomide 14 mg/day vs placebo demonstrated disability increase. Treatment was well tolerated; numbers of adverse events and serious adverse events were similar in all treatment groups. Oral teriflunomide was effective in reducing MRI lesions and was well tolerated in patients with relapsing multiple sclerosis.